10.05.2017
Prevent & Delay
$660,000.00
36 months
Engineering Treg antigen specificity and stability for the treatment of T1D
Funds support a work into a preclinical proof-of-principle for an engineered targeted Treg cell therapy to treat type 1 diabetes.